From mandating animal testing to ending the requirement: the history of drug safety regulation and the rise of New Approach Methodologies
After 107 people died from an untested toxic solvent in a sulfanilamide elixir, Congress passed the FD&C Act requiring pre-market safety testing. Section 505(i) established animal testing as the mandatory method for demonstrating drug safety before human trials.
The Animal Welfare Act established minimum care standards for animals used in research, but explicitly exempted mice, rats, and birds - which comprise over 95% of animals used in drug testing. The act acknowledged concerns but didn't provide alternatives.
The National Academy of Sciences released a landmark report calling for a paradigm shift away from animal testing toward human-relevant in vitro and computational methods. This report laid the scientific foundation for what would become New Approach Methodologies (NAMs).
This act encouraged FDA to consider alternatives to animal testing and established programs to evaluate new methodologies. It created pathways for breakthrough therapies and expanded the FDA's authority to accept innovative testing approaches, though animal testing remained the default requirement.
Signed into law by President Biden on December 29, 2022, this historic legislation amended Section 505(i) to remove the 84-year-old mandate requiring animal testing. For the first time, drug developers could choose NAMs like organoids, organ-on-chip, and computational models for preclinical testing.
Building on FDA Mod Act 2.0, this legislation extended the principles to cosmetics, explicitly banning animal testing for cosmetic products and establishing NAMs as the preferred testing method for personal care products.
Dive deeper into the FDA Modernization Act and what it means for drug development
Complete FDA Guide NAMs Ecosystem Regulatory Hub